RecruitingNCT06163534

A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

TEMPUS PHOENIX HNSCC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

Sponsor

Tempus AI

Enrollment

500 participants

Start Date

Aug 1, 2024

Study Type

OBSERVATIONAL

Conditions

Head and Neck Squamous Cell Carcinoma

Summary

The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is an observational (non-treatment) study that collects detailed biological samples — blood, tissue, and other specimens — from people with head and neck squamous cell carcinoma (cancer of the mouth, throat, or larynx). Researchers will analyze these samples over time to identify biological markers that predict how patients respond to treatment. **You may be eligible if...** - You are 18 or older with confirmed metastatic or unresectable head and neck squamous cell carcinoma (HNSCC) - You are about to start first-line immunotherapy (anti-PD-1 or anti-PD-L1 based) - You are willing to provide blood samples and tumor biopsies **You may NOT be eligible if...** - You have already started treatment for your current cancer episode - You are unable or unwilling to provide required tissue and blood samples Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(30)

City of Hope

Duarte, California, United States

USC/Norris Comprehensive Cancer Center

Los Angeles, California, United States

University of California, Los Angeles

Los Angeles, California, United States

Stanford

Palo Alto, California, United States

Providence Medical Foundation

Santa Rosa, California, United States

Morehouse

Atlanta, Georgia, United States

Piedmont Healthcare

Atlanta, Georgia, United States

Winship Cancer Institute, Emory University

Atlanta, Georgia, United States

Northwestern University Feinberg School of Medicine

Chicago, Illinois, United States

Cancer Care Specialists of Illinois

Decatur, Illinois, United States

Illinois Cancer Care

Peoria, Illinois, United States

University of Kansas

Westwood, Kansas, United States

University of Maryland

Baltimore, Maryland, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Henry Ford

Detriot, Michigan, United States

Karmanos Cancer Institute

Detroit, Michigan, United States

Oncology Hematology Associates

Springfield, Missouri, United States

Washington University in St. Louis

St Louis, Missouri, United States

Mount Sinai Hospital

New York, New York, United States

Sanford Fargo

Fargo, North Dakota, United States

University of Cincinnati

Cincinnati, Ohio, United States

Cleveland Clinic

Cleveland, Ohio, United States

Ohio State University

Columbus, Ohio, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Cancer Care Associates of York

York, Pennsylvania, United States

Sanford Sioux Falls

Sioux Falls, South Dakota, United States

Vanderbilt University

Nashville, Tennessee, United States

University of Washington

Seattle, Washington, United States

ThedaCare

Appleton, Wisconsin, United States

Pan American Cancer for Oncology

San Juan, Puerto Rico

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06163534

Related Trials

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

NCT06525220202 locations

(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma

NCT057476251 location

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

NCT074623776 locations

Compartmentalized Postoperative Radiotherapy in Head and Neck Cancer

NCT070588053 locations

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

NCT0630524712 locations